Quick Search:

uzh logo
Browse by:
bullet
bullet
bullet
bullet

Zurich Open Repository and Archive

Permanent URL to this publication: http://dx.doi.org/10.5167/uzh-48014

Zardavas, D; Meisel, A; Samaras, P; Knuth, A; Renner, C; Pestalozzi, B C; Stenner-Liewen, F (2011). Temsirolimus is highly effective as third-line treatment in chromophobe renal cell cancer. Case Reports in Oncology, 4(1):16-18.

[img]
Preview
Published Version
PDF
1MB

View at publisher
[img]Supplemental Material
Video (AVI) (Video 1)
13MB
[img]Supplemental Material
Video (AVI) (Video 2)
14MB

Abstract

We report unexpectedly high efficacy of temsirolimus as third-line treatment in a patient with metastatic chromophobe renal cell carcinoma. After failure of two sequentially administered tyrosine kinase inhibitors, treatment with temsirolimus resulted in a prolonged partial remission of 14 months, and the response is still continuing. Up to now, no data from randomized clinical studies have been published addressing the question of efficacy of temsirolimus as third-line treatment after failure of tyrosine kinase inhibitors. The case presented here implies that temsirolimus could be a viable option for patients with metastatic chromophobe renal cell carcinoma.

Citations

Altmetrics

Downloads

80 downloads since deposited on 06 May 2011
22 downloads since 12 months

Detailed statistics

Additional indexing

Item Type:Journal Article, refereed, original work
Communities & Collections:04 Faculty of Medicine > University Hospital Zurich > Clinic for Oncology
DDC:610 Medicine & health
Language:English
Date:2011
Deposited On:06 May 2011 11:15
Last Modified:08 Oct 2014 07:35
Publisher:Karger
ISSN:1662-6575
Publisher DOI:10.1159/000323804
PubMed ID:21526001

Users (please log in): suggest update or correction for this item

Repository Staff Only: item control page